In a report released today, Stephen Unger from Needham maintained a Buy rating on Danaher (DHR), with a price target of $187.00. The company’s shares closed last Monday at $124.19, close to its 52-week low of $121.07.
According to TipRanks.com, Unger is a 4-star analyst with an average return of 3.8% and a 51.0% success rate. Unger covers the Healthcare sector, focusing on stocks such as Myriad Genetics, Thermo Fisher, and PerkinElmer.
Currently, the analyst consensus on Danaher is a Moderate Buy with an average price target of $174.00.
See today’s analyst top recommended stocks >>
Based on Danaher’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $824 million. In comparison, last year the company had a net profit of $747 million.
Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year. Last month, William King, the SVP, Strategic Development of DHR sold 26,370 shares for a total of $4,225,041.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions.
